mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.048 |
0.2 |
mRNA |
trifluoperazine |
CTRPv2 |
pan-cancer |
AAC |
0.055 |
0.2 |
mRNA |
selumetinib:navitoclax (8:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.051 |
0.2 |
mRNA |
CD-1530 |
CTRPv2 |
pan-cancer |
AAC |
0.053 |
0.2 |
mRNA |
BRD-K92856060 |
CTRPv2 |
pan-cancer |
AAC |
0.05 |
0.2 |
mRNA |
tandutinib |
CTRPv2 |
pan-cancer |
AAC |
0.051 |
0.2 |
mRNA |
CIL70 |
CTRPv2 |
pan-cancer |
AAC |
0.067 |
0.2 |
mRNA |
BRD-K58730230 |
CTRPv2 |
pan-cancer |
AAC |
0.11 |
0.2 |
mRNA |
importazole |
CTRPv2 |
pan-cancer |
AAC |
0.054 |
0.2 |
mRNA |
isoevodiamine |
CTRPv2 |
pan-cancer |
AAC |
0.046 |
0.2 |